novel
coronaviru
caus
pandem
threaten
million
protect
immun
exist
human
viru
capabl
escap
innat
immun
respons
prolifer
unhind
primarili
infect
tissu
subsequ
cell
death
result
releas
viru
particl
intracellular
compon
extracellular
space
result
immun
cell
recruit
gener
immun
complex
associ
damag
infect
monocytesmacrophag
andor
recruit
uninfect
immun
cell
result
massiv
inflammatori
respons
later
diseas
uncontrol
product
proinflammatori
mediat
contribut
ard
cytokin
storm
syndrom
antivir
agent
immun
modul
treatment
current
triall
understand
immun
evas
strategi
result
delay
massiv
immun
respons
result
identif
biomark
predict
outcom
well
phenotyp
diseas
stage
specif
treatment
like
includ
antivir
immun
modul
agent
sar
outbreak
coronavirus
cov
showcas
potenti
epidem
spread
signific
pathogen
human
mainli
known
caus
mild
respiratori
gastrointestin
diseas
last
two
decad
three
novel
betacoronavirus
sever
acut
respiratori
syndrom
sar
cov
middl
east
respiratori
syndrom
mer
cov
cross
speci
barrier
caus
signific
outbreak
character
high
casefat
rate
human
latest
addit
human
pathogen
coronavirus
hcov
caus
time
submiss
review
infect
million
peopl
worldwid
claim
live
threaten
mani
http
gisanddata
mapsarcgiscomappsopsdashboardindexhtml
follow
epidemiolog
clinic
featur
pathophysiolog
mechan
alreadi
avail
futur
therapeut
option
discuss
base
limit
evid
avail
extrapol
relat
viral
diseas
first
hcov
describ
part
group
current
four
known
season
hcov
shcov
also
includ
discov
shcov
global
endem
frequent
caus
common
cold
account
respiratori
tract
infect
fourth
birthday
children
show
antibodi
direct
least
one
shcov
antishcov
antibodi
provid
crossimmun
antibodymedi
protect
infect
speci
within
group
overal
pathogen
potenti
compar
low
immunocompromis
infant
elderli
preexist
pulmonari
disord
shcov
caus
sever
respiratori
sepsislik
present
display
neurotrop
caus
demyelin
cn
infect
vulner
patient
group
estim
contribut
annual
respiratori
ill
vari
shcov
remain
asymptomat
approxim
case
stark
contrast
clinic
present
encount
infect
socal
novel
coronavirus
sarscov
merscov
associ
morbid
casefat
ratio
far
exceed
one
shcov
sar
pandem
origin
foshan
guangdong
provinc
china
spread
south
east
asia
europ
north
america
contain
declar
end
reemerg
report
sinc
overal
probabl
case
caus
death
result
mortal
rate
http
wwwwhointcsr
sarsen
mortal
strongli
correl
age
approach
younger
older
year
health
care
worker
contact
sar
patient
demonstr
low
seroconvers
rate
asymptomat
individu
less
affect
children
postcontain
seropreval
among
http
receiv
april
children
consid
highrisk
signific
exposur
extrem
low
suggest
subclin
sar
among
children
occur
approxim
sar
patient
requir
intens
care
support
acut
respiratori
distress
syndrom
ard
half
die
within
follow
day
sever
clinic
phenotyp
sar
replic
emerg
mer
continu
circul
albeit
lesser
extent
date
case
mer
occur
worldwid
present
sever
pneumonia
result
respiratori
multiorgan
failur
casefatalityratio
individu
comorbid
male
immunocompromis
consid
particularli
high
risk
previou
novel
coronaviru
outbreak
sever
clinic
manifest
puzzl
clinician
common
featur
includ
massiv
inflammatori
cell
infiltr
lung
result
acut
lung
injuri
ali
ard
highli
elev
inflammatori
marker
serum
evid
monocytemacrophag
activ
activ
coagul
proinflammatori
cytokin
chemokin
profil
soon
led
implic
host
respons
import
factor
fulmin
diseas
process
anim
model
sar
suggest
lung
inflamm
intensifi
viral
clearanc
peak
late
day
infect
similar
observ
made
human
sar
patient
suggest
clinic
deterior
later
diseas
cours
like
due
uncontrol
viral
replic
rather
uncontrol
immun
respons
associ
damag
similar
descript
clinic
present
emerg
present
featur
cough
fever
subacut
progress
respiratori
distress
acut
respiratori
distress
sydrom
ard
patient
elderli
underli
comorbid
especi
cardiovascular
diseas
diabet
mellitu
chronic
pulmonari
disord
renal
diseas
especi
risk
http
www
engpdf
estim
patient
develop
respiratori
symptom
requir
supplement
oxygen
approxim
develop
need
mechan
ventil
cdc
report
overal
casefat
rate
though
higher
patient
year
age
among
critic
ill
requir
mechan
ventil
pulmonari
patholog
character
diffus
alveolar
damag
focal
reactiv
hyperplasia
pneumocyt
patchi
inflammatori
cellular
infiltr
evid
intravascular
thrombosi
monocyt
macrophag
lymphocyt
infiltr
pulmonari
interstitium
sever
pulmonari
inflammatori
infiltr
pulmonari
tissu
imped
alveolar
ga
exchang
addit
one
fifth
hospit
patient
develop
signific
cardiovascular
morbid
character
troponin
rise
tachyarrhythmia
thromboembol
event
strongli
associ
mortal
risk
common
featur
patient
requir
hospit
intens
care
level
support
therefor
sever
pneumonia
hypox
respiratori
failur
subacut
onset
evolv
ard
clinic
pictur
character
fever
lymphopenia
highli
elev
creactiv
protein
proinflammatori
cytokin
serum
ferritin
ddimer
histopatholog
evid
promin
pulmonari
infitr
domin
monocyt
macrophag
vascul
hypercoagul
seen
base
current
knowledg
clinic
pictur
diseas
patholog
progress
infect
similar
caus
signific
morbid
mortal
may
associ
hyperinflammatori
respons
subset
patient
viral
structur
host
rang
cell
entri
mechan
coronavirus
highli
preval
anim
pathogen
wide
host
rang
overal
thousand
speci
coronavirus
known
current
seven
cov
recogn
human
pathogen
famili
coronavirida
divid
two
subfamili
coronavirina
torovirina
coronavirina
includ
genera
alpha
betacoronavirus
infect
mammal
gamma
deltacoronavirus
infect
mammal
bird
human
cov
human
pathogen
alpha
novel
cov
includ
betacoronavirus
potenti
torovirus
caus
diseas
human
unknown
http
coronavirus
cov
larg
envelop
virus
singlestrand
nonseg
posit
sens
rna
genom
span
approxim
kilobas
make
largest
known
genom
rna
viru
rna
virus
cov
readili
evolv
mutat
homolog
nonhomolog
recombin
expand
host
rang
facilit
cross
speci
barrier
extens
anim
reservoir
especi
among
bat
genet
recombin
among
cov
plastic
term
receptor
use
render
cov
highli
effect
host
switch
sometim
across
wide
taxonom
distanc
hcov
thought
zoonos
novel
coronavirus
sarscov
merscov
compar
poorli
adapt
human
affect
pathogen
potenti
genom
proxim
anim
cov
may
allow
ongo
interspeci
recombin
event
observ
mer
merscov
sarscov
natur
reservoir
bat
infect
human
like
occur
intermedi
host
includ
dromedari
camel
mer
mask
palm
civet
sar
pangolin
wild
palm
civet
carri
sarscov
must
assum
proxim
anim
market
facilit
recombin
event
emerg
novel
virus
may
pathogen
human
coronavirus
spheric
shape
promin
featur
clublik
project
viru
surfac
refer
spike
viru
membran
contain
four
structur
compon
spike
envelop
e
membran
nucelocapsid
n
protein
fig
sarscov
protein
primari
determin
host
tropism
pathogen
main
target
neutral
antibodi
therefor
great
interest
term
immunolog
respons
vaccin
design
spike
structur
form
homotrim
sglycoprotein
consist
two
subunit
wherebi
form
part
involv
receptor
recognit
highli
conserv
anchor
protein
viral
membran
facilit
viral
fusion
contain
hypervari
loop
differ
greatli
betacoronavirus
size
sequenc
viral
entri
requir
proteolysi
protein
two
locat
process
util
host
proteas
result
irrevers
conform
chang
protein
antisarscov
antibodi
human
mimic
receptor
engag
thu
model
conform
protein
chang
upon
antigenantibodi
interact
amino
acid
sequenc
receptor
bind
site
homolog
sarscov
suggest
similar
even
ident
cell
entri
mechan
virus
sarscov
use
transmembran
angiotensin
convert
enzym
ace
host
receptor
wherea
mer
cov
util
receptor
transmembran
ectoenzym
highli
conserv
among
mammal
thu
facilit
interspeci
transfer
howev
enzymat
activ
necessari
success
bind
fusion
bind
affin
protein
high
high
sequenc
conform
conserv
protein
observ
across
sarscov
allow
level
cross
neutral
two
virus
vitro
hemagglutinin
residu
enhanc
bind
allow
interact
sialic
acid
residu
host
cell
surfac
betacoronavirus
featur
yet
anoth
structur
protein
hemagglutininesteras
bind
sialic
acid
cell
surfac
fig
may
enhanc
viru
abil
bind
invad
host
cell
surfac
may
constitut
virul
factor
novel
hcov
estim
infect
asymptomat
result
mild
diseas
remain
patient
sever
critic
unwel
current
limit
inform
avail
host
factor
affect
individu
outcom
data
still
spars
aforement
parallel
sarscov
merscov
may
allow
extrapol
knowledg
understand
escap
host
immun
respons
notabl
share
almost
rna
sequenc
homolog
sarscov
merscov
exhibit
addit
genom
region
compar
sarscov
particular
viral
spike
protein
bind
host
cell
receptor
amino
acid
longer
sarscov
close
relat
coronavirus
thu
possibl
even
like
use
similar
immun
evas
strategi
coronavirus
addit
yet
undiscov
mechan
may
also
util
mention
sarscov
use
host
cell
receptor
establish
infect
fig
express
almost
organ
bodi
shown
highli
express
surfact
produc
type
alveolar
cell
ciliat
goblet
cell
airway
cell
like
provid
portal
entri
viru
human
high
express
also
observ
intestin
epithelium
furthermor
express
cardiac
cell
vascular
endothelia
may
explain
cardiovascular
complic
patient
sarscov
infect
immun
cell
includ
monocytesmacrophag
cell
observ
clear
date
whether
extent
also
infect
cell
type
also
lower
level
ubiquit
express
monocyt
macrophag
may
also
provid
entri
mechan
immun
cell
howev
receptor
andor
phagocytosi
viru
contain
immun
complex
may
also
involv
fig
host
respons
clearanc
viral
infect
heavili
reli
type
interferon
express
express
downstream
signal
modul
cell
respons
reprogram
cell
antivir
state
subsequ
promot
infect
control
pathogen
clearanc
first
step
immun
cell
sens
viral
infect
identif
viru
deriv
pattern
associ
molecular
pattern
pamp
viral
rna
bind
activ
pattern
recognit
receptor
prr
inon
immun
cell
result
immun
cell
activ
fig
rna
virus
sarscov
merscov
detect
endosom
rna
prr
includ
tolllik
receptor
tlr
andor
cytoplasm
rna
sensor
name
retino
acidinduc
gene
rigi
melanoma
differentiationassoci
protein
fig
usual
activ
result
nuclear
transloc
transcript
factor
activ
result
activ
turn
trigger
increas
express
innat
proinflammatori
cytokin
context
innat
proinflammatori
cytokin
promot
express
autoamplif
activ
receptor
complex
ifnar
result
phosphorylationactiv
stat
famili
transcript
factor
fig
tnf
receptor
activ
feed
proinflammatori
cytokin
express
though
transcript
factor
fig
activ
prime
innat
adapt
immun
respons
result
pathogen
clearanc
recoveri
howev
proport
infect
individu
sarscov
merscov
like
evad
immun
system
recognit
suppress
mechan
phenomenon
associ
sever
diseas
poorer
prognosi
fig
red
symbol
sarscov
shown
alter
ubiquitin
degrad
rna
sensor
rigi
inhibit
activ
mitochondri
antiviralsign
protein
mav
essenti
activ
nuclear
transloc
respons
cytoplasm
rna
sensor
activ
furthermor
sarscov
like
inhibit
tnf
receptorassoci
factor
traf
central
induct
respons
andor
rigi
ligat
well
signal
pathway
usual
activ
respons
ligat
cytokin
receptor
signal
lastli
novel
coronavirus
counteract
signal
inhibit
stat
famili
transcript
factor
phosphoryl
taken
togeth
suppress
innat
immun
mechan
infect
epitheli
cell
extent
infect
monocytesmacrophag
allow
novel
coronavirus
prolifer
without
trigger
innat
antivir
respons
machineri
cell
howev
later
stage
infect
cell
undergo
cell
death
releas
viru
particl
togeth
intracellular
compon
trigger
innat
inflammatori
mechan
recognit
prr
innat
immun
cell
result
innat
immun
activ
result
express
proinflammatori
cytokin
includ
etc
adapt
immun
cell
becom
involv
host
defens
viral
infect
lymphocyt
play
central
role
antivir
respons
includ
cell
deriv
cytokin
cell
mediat
cytotox
b
cell
activ
result
antibodi
product
novel
coronavirus
may
also
partial
escap
mechan
induct
cell
apoptosi
howev
lymphocyt
may
also
becom
deplet
due
express
proinflammatori
cytokin
infect
innat
immun
cell
becom
recruit
lung
trigger
hyperinflamm
seen
develop
cytokin
storm
symptom
diseas
may
sometim
slightli
milder
comparison
infect
sarscov
merscov
sever
key
pathogenassoci
clinic
featur
diseas
similar
extrapol
knowledg
alreadi
known
pathophysiolog
sar
mer
sar
mer
sever
key
find
associ
poor
outcom
cohort
studi
suggest
hyperinflamm
may
link
sever
diseas
three
earli
studi
wuhan
link
cytopenia
andor
significantli
elev
inflammatori
paramet
sever
diseas
unfavor
outcom
one
studi
involv
patient
report
neutrophilia
lymphopenia
increas
system
inflammatori
protein
crp
common
symptom
diseas
anoth
studi
involv
individu
link
sever
diseas
culmin
icu
admiss
mortal
neutrophilia
lymphopenia
third
studi
report
signific
leukopenia
lymphopenia
thrombopenia
anemia
hypofibrinogenemia
hypoalbuminemia
cohort
patient
die
observ
line
find
sever
lethal
case
sar
mer
increas
number
neutrophil
monocyt
macrophag
present
airway
group
report
sever
clinic
phenotyp
icu
depend
patient
associ
increas
plasma
level
innat
chemokin
specif
cxc
motif
chemokin
interferon
gammainduc
protein
chemokin
cc
motif
ligand
monocyt
chemoattract
protein
macrophag
inflammatori
protein
mip
proinflammatori
cytokin
inde
similar
situat
report
sar
mer
uncontrol
inflamm
central
contribut
poor
outcom
though
seemingli
contradictori
mechan
immun
evas
discuss
enhanc
innat
immun
activ
includ
increas
express
central
contribut
morbid
mortal
mer
sar
one
possibl
explan
induct
endotheli
vascular
cell
damag
cell
death
result
viral
replic
virusinduc
inflammatori
cell
death
includ
necrosi
pyroptosi
result
proinflammatori
cytokin
express
uninfect
immun
cell
recruit
activ
mice
infect
sarscov
exhibit
fig
immun
evas
strategi
infect
airway
epitheli
cell
interact
transmembran
enzym
rna
virus
usual
activ
andor
endosom
b
cytosol
rna
sensor
rigi
c
effect
suppress
activ
tnf
receptorassoci
factor
traf
therebi
limit
activ
transcript
factor
therebi
suppress
earli
proinflammatori
respons
type
interferon
ifn
proinflammatori
effector
cytokin
red
symbol
furthermor
novel
cov
inhibit
activ
stat
transcript
factor
respons
type
ifn
receptor
activ
limit
antivir
respons
mechan
altogeth
prohibit
viru
contain
activ
antivir
program
recruit
immun
cell
b
tissu
monocytesmacrophag
express
significantli
lower
extent
make
infect
rout
less
like
howev
immun
complex
consist
ineffect
antibodi
eg
season
cov
viru
particl
may
taken
macrophag
receptor
result
infect
b
process
refer
antibodi
direct
enhanc
ade
virion
inhibit
type
ifn
signal
infect
macrophag
allow
proinflammatori
express
may
contribut
hyperinflamm
cytokin
storm
syndrom
c
inhibit
type
ifn
signal
suppress
antivir
program
increas
express
autoamplifi
posit
feedback
loop
f
excess
secret
myeloid
cell
infect
tissu
inde
immun
evas
suppress
antivir
respons
express
respiratori
epithelia
result
high
viral
load
hypothes
infect
monocyt
macrophag
neutrophil
recruit
site
infect
exhibit
strong
poorli
control
inflammatori
respons
result
tissu
damag
system
inflamm
contribut
morbid
mortal
fig
anoth
factor
thought
contribut
organ
damag
poor
outcom
earli
product
neutral
antibodi
coronavirus
antibodydepend
enhanc
ade
phenomenon
shown
contribut
damag
accrual
viral
infect
shown
promot
cellular
uptak
viru
particl
bound
immun
complex
bind
receptor
may
contribut
aforement
persist
viral
replic
immun
cell
includ
newli
infect
antigenpres
cell
also
immun
complex
mediat
inflammatori
respons
fig
contribut
tissu
organ
damag
includ
acut
respiratori
distress
syndrom
ard
inde
subset
patient
reportedli
develop
vasculit
lesion
blood
vessel
occlus
infarct
histopatholog
report
tissu
section
suggest
featur
associ
immun
complex
mediat
vascul
includ
infiltr
monocyt
lymphocyt
within
around
blood
vessel
wall
thicken
focal
hemorrhag
true
number
system
autoimmuneinflammatori
condit
uncontrol
activ
immun
respons
like
limit
innat
mechan
result
proinflammatori
cytokin
express
presenc
nuclear
antigen
cell
tissu
damag
adapt
immun
cell
may
becom
activ
trigger
second
wave
inflamm
potenti
patient
deterior
day
infect
inde
adapt
immun
cell
name
lymphocyt
observ
lung
tissu
section
patient
ard
andor
cytokin
storm
may
drive
inflamm
later
diseas
stage
similar
mechan
report
influenza
viral
infect
overal
sever
ill
patient
experienc
cytokin
storm
exhibit
lymphopenia
sometim
atrophi
lymphat
tissu
name
lymph
node
spleen
line
report
primari
secondari
form
hemophagocyt
lymphohistiocytosi
hlh
associ
cytokin
storm
result
inflammatori
cell
death
hypocellular
lymphat
organ
poor
outcom
associ
age
inde
children
appear
contract
usual
develop
sever
symptom
fig
inflammatori
respons
monocyt
macrophag
uninfect
monocytesmacrophag
blood
stream
invad
lung
detect
viru
particl
andor
cytoplasm
nuclear
compon
within
immun
complex
particl
taken
cell
present
tlr
activ
andor
irf
depend
proinflammatori
pathway
b
c
result
uninfect
monocytesmacrophag
produc
signific
amount
proinflammatori
cytokin
e
recruit
addit
innat
adapt
immun
cell
caus
addit
tissu
damag
complic
surpris
children
prone
viral
infect
includ
sever
manifest
children
get
expos
season
coronavirus
th
birthday
seroconvert
howev
antibodi
titr
wane
time
obviou
year
may
reduc
immun
respons
elderli
limit
crossreact
antiseason
coronaviru
antisar
antibodi
exist
also
contribut
increas
inflamm
complic
immunolog
recal
effect
exist
antiseason
coronaviru
titr
increas
sera
convalesc
sar
patient
may
influenc
immun
patholog
mention
antibodybound
virion
enter
suscept
cell
macrophag
receptor
ligat
process
term
antibodydepend
enhanc
ade
viral
infect
eg
dengu
fever
ade
allow
immun
cell
infect
reduc
type
ifn
depend
antivir
respons
promot
proinflammatori
express
furthermor
massiv
recal
antibodi
product
individu
histori
exposur
season
coronavirus
wane
titr
elderli
result
immun
complex
deposit
promot
inflamm
damag
includ
immun
complex
vascul
anoth
agedepend
diseas
mechan
may
associ
live
vaccin
eg
measl
bcg
vaccin
protect
beyond
target
antigen
induct
innat
immun
mechan
term
nonspecif
heterolog
effect
individu
receiv
bcg
vaccin
produc
increas
level
proinflammatori
respons
aureu
candida
spp
bcg
vaccin
infant
exhibit
reduc
infectionrel
mortal
howev
heterolog
immun
respons
unrel
antigen
may
also
contrit
inflammationrel
complic
frequent
adult
exhibit
memori
cell
specif
antigen
never
expos
crossreact
memori
cell
narrow
cell
respons
favor
high
affin
clone
inde
limit
memori
cell
repertoir
featur
immun
senesc
associ
diseas
progress
cell
mediat
damag
viral
infect
viru
hepat
infect
mononucleosi
mention
act
transmembran
cellular
receptor
allow
cell
infect
variabl
express
pattern
affect
diseas
suscept
tissu
eg
respiratori
epithelia
vs
immun
cell
potenti
also
individu
men
vs
women
children
vs
adult
therebi
determin
diseas
progress
outcom
recent
suggest
express
highest
children
young
women
express
decreas
age
lowest
individu
chronic
diseas
includ
diabet
hypertens
invers
correl
risk
sever
diseas
unfavor
outcom
facilit
viral
entri
cell
also
play
role
control
infect
inflamm
part
ma
system
counteract
proinflammatori
effect
catalyz
process
counteract
vasoconstrict
modul
leukocyt
migrat
cytokin
express
fibrogen
pathway
thu
contribut
limit
tissu
inflamm
favor
repair
mechan
furthermor
high
express
may
benefit
viru
particl
may
compet
cell
surfac
bind
site
cellular
uptak
thu
rel
increas
express
may
explain
children
young
adult
especi
young
women
rel
protect
associ
complic
taken
togeth
novel
coronavirus
may
effect
suppress
earli
respons
contribut
uncontrol
viru
replic
result
delay
potenti
increas
cytokin
respons
later
stage
earli
suffici
control
viru
replic
pathogen
clearanc
may
alter
individu
risk
elderli
patient
diabet
metabol
syndrom
etc
healthi
children
young
peopl
hand
may
effect
control
viral
load
earli
stage
infect
less
frequent
develop
sever
diseas
lifethreaten
complic
lastli
earli
antibodi
product
may
result
integr
viabl
viru
immun
cell
increas
viral
replic
result
immun
complex
mediat
patholog
may
contribut
patholog
young
patient
obviou
risk
factor
rapid
spread
infect
global
led
immedi
need
vaccin
therapeut
intervent
prevent
treat
diseas
due
speed
viru
spread
global
studi
potenti
therapeut
intervent
vaccin
candid
due
minim
sever
sar
death
global
mer
death
global
epidem
studi
gener
vaccin
therapeut
close
relat
coronavirus
undertaken
could
efficaci
diseas
clinic
trial
test
treatment
undertaken
result
larg
random
studi
though
remain
outstand
stage
result
follow
section
mistaken
evid
base
treatment
recommend
reflect
mostli
anecdot
experi
experiment
treatment
extrapol
data
relat
condit
expert
opinion
fig
medic
use
chloroquin
date
back
decad
phosphat
sulphat
deriv
administ
antimalari
hydroxychloroquin
wide
use
immunomodulatori
agent
system
lupu
erythematosu
addit
chloroquin
antivir
activ
influenza
chikungunya
viru
season
cov
sar
virus
cell
entri
replic
depend
phdepend
intern
endocytosi
lysosom
fusion
fig
weak
base
hydroxychloroquin
follow
cellular
ph
gradient
accumul
acid
environ
endolysosom
acid
cell
organel
therebi
alkalin
endosom
addit
hydroxychloroquin
interfer
termin
glycosyl
interf
viru
bind
antivir
activ
chloroquin
deriv
identifi
vitro
earli
base
drug
rapidli
introduc
clinic
use
preliminari
report
suggest
improv
viral
clearanc
clinic
outcom
patient
receiv
cours
hydroxychloroquin
small
french
pilot
studi
random
patient
suggest
acceler
viral
clearanc
patient
treat
combin
hydroxychloroquin
azithromycin
howev
other
challeng
result
found
benefit
either
diseas
outcom
viral
clearanc
disappointingli
largest
also
retrospect
studi
date
assess
hydroxychloroquin
combin
azithromycin
found
benefit
inde
increas
mortal
risk
among
patient
receiv
hydroxychloroquin
studi
explor
chloroquin
diphosph
two
dose
regimen
forc
termin
earli
concern
increas
mortal
high
dose
arm
author
conclud
treatment
high
dose
chloroquin
day
suffici
safe
longer
use
sever
patient
immunomodulatori
effect
hydroxychloroquin
well
establish
may
enhanc
therapeut
effect
complic
macrophag
activ
cytokin
storm
alkal
endosom
reduc
proteolysi
chemotaxi
phagocytosi
receptor
recycl
interfer
process
epitop
display
antigenpres
cell
overal
contribut
decreas
product
prostaglandin
alter
intracellular
calcium
tlr
depend
signal
furthermor
prevent
acidif
lysosom
hydroxychloroquin
impair
cellular
autophagi
critic
step
innat
adapt
immun
activ
final
hydroxychloroquin
antithrombot
effect
may
benefici
inflammatori
stimuli
endotheli
injuri
activ
coagul
promot
microthrombu
format
gener
deem
safe
administ
correct
dose
close
monitor
therapeut
rang
chloroquin
deriv
narrow
side
effect
includ
conduct
defect
cardiomyopathi
retinopathi
hypoglycemia
mention
synergist
effect
azithromycin
hydroxychloroquin
observ
vitro
appear
translat
clinic
practic
interestingli
azithromycin
also
weak
base
also
accumul
endosom
alkalin
effect
least
equival
hydroxychloroquin
addit
antimicrobi
properti
azithromycin
sometim
use
immunomodulatori
properti
especi
patient
chronic
pulmonari
disord
azithromycin
polar
macrophag
toward
antiinflammatori
phenotyp
inhibit
proinflammatori
signal
pathway
context
antiinflammatori
effect
particular
interest
azithromycin
use
patient
requir
intens
care
relat
ard
associ
signific
reduct
mortal
shorter
time
extub
advers
cardiac
effect
proarrhythmogen
properti
hydroxychloroquin
especi
combin
macrolid
antibiot
azithromycin
deserv
particular
mention
hydroxychloroquin
azithromycin
lesser
extent
lopinavir
associ
prolong
qtc
interv
increas
risk
tachyarrhythmia
sudden
cardiac
death
care
consider
patient
risk
profil
pretreat
ecg
assess
monitor
pharmacokinet
fluid
electrolyt
statu
polypharmaci
essenti
manag
critic
ill
covid
patient
nucleosid
analogu
explor
treatment
option
candid
includ
favipiravir
geldesivir
ribavirin
remdesivir
latter
receiv
attent
remdesivir
prodrug
adenosin
origin
develop
treatment
hemorrhag
fever
virus
name
ebola
ebov
marburg
virus
underperform
ebov
treatment
compar
antibodi
strategi
antivir
vitro
activ
mer
sar
compet
atp
substitut
adenosin
rna
synthesi
remdesivir
inhibit
viral
rna
depend
rna
polymeras
rdrp
human
mitochondri
rdrp
show
significantli
lower
affin
remdesivir
compar
viral
counterpart
mitig
side
effect
host
cell
presenc
covspecif
proofread
exonucleas
capabl
remov
phosphoryl
remdesivir
rna
chain
could
present
potenti
develop
resist
remdesivir
treatment
murin
hepat
viru
mous
model
show
confer
resist
tradeoff
viral
fit
magnitud
suffici
significantli
attenu
viral
pathogen
time
administr
anim
model
ebov
mer
crucial
remdesivir
efficaci
benefit
achiev
given
earli
keep
aforement
phase
diseas
highest
viru
replic
rate
earli
diseas
hostmedi
damag
immun
respons
later
stage
recent
case
report
howev
highlight
persist
benefit
also
late
administr
remdesivir
underw
vitro
test
wuhan
viru
research
institut
earli
outbreak
identifi
potent
inhibit
viral
infect
cell
cultur
concentr
readili
achiev
vivo
first
use
success
patient
januari
sinc
remdesivir
employ
compassion
use
basi
result
use
day
cours
report
patient
requir
ecmo
mechan
ventil
baselin
significantli
reduc
mortal
assess
random
control
trial
need
two
place
china
treatment
moder
sever
recruit
termin
march
follow
declar
contain
trial
current
ongo
europ
north
america
effect
reduct
pulmonari
viral
load
anim
model
accept
safeti
profil
ebola
patient
small
group
patient
remdesivir
may
offer
effect
viabl
futur
treatment
option
combin
lopinavir
ritonavir
lpvr
better
known
tradenam
frequent
use
antiretrovir
treatment
hiv
combin
two
proteas
inhibitor
limit
otherwis
extens
activ
drug
metabol
therebi
result
much
improv
bioavail
lpv
proteas
critic
approv
evidencebas
treatment
avail
number
treatment
promis
potenti
viru
particl
may
caught
inactiv
use
antibodi
convalesc
patient
recombin
solubl
protein
may
bind
andor
mediat
antiinflammatori
effect
prevent
pulmonari
damag
hyperinflamm
hydroxi
chloroquin
potenti
combin
azithromycin
chang
ph
endosom
reduc
viru
entri
replic
furthermor
medic
immunemodul
effect
may
control
proinflammatori
cytokin
express
antivir
treatment
proteas
inhibitor
lopinavir
ritonavir
etc
andor
nucleosid
analogu
remdesivir
etc
limit
viru
replic
suppress
antivir
cytokin
product
viru
clearanc
may
also
support
substitut
type
interferon
activ
cytokin
receptor
ifnar
induc
antivir
cellular
program
hyperinflamm
result
tissu
damag
may
prevent
immun
modul
block
signal
eg
recombin
receptor
antagonist
anakinra
signal
eg
receptor
antibodi
tocilizumab
may
limit
immun
activ
tissu
damag
cytokin
storm
addit
less
specif
effect
may
mediat
corticosteroid
immunoglobulin
hydroxychloroquin
andor
azithromycin
viral
replic
cleav
structur
function
protein
precursor
viral
polypeptid
fig
thu
enabl
matur
infecti
virion
particl
lpvr
mainli
metabol
liver
thu
preexist
hepat
impair
consid
rel
contraind
sar
lpvr
combin
ribavirin
associ
signific
reduct
unfavor
outcom
ard
death
compar
ribavirin
alon
versu
similar
observ
made
retrospect
cohort
studi
involv
sar
patient
lpvr
associ
significantli
reduc
mortal
need
intub
current
investig
use
mer
patient
ongo
random
clinic
trial
earli
use
lpvr
recommend
base
aforement
pathophysiolog
consider
rather
clinic
data
view
vitro
activ
sar
mer
limit
clinic
data
avail
lpvr
treatment
critic
ill
patient
random
openlabel
trial
undertaken
wuhan
china
recruit
almost
patient
random
either
standard
treatment
ad
lpvr
day
whilst
confirm
safeti
lpvr
use
signific
differ
seen
group
relat
surviv
time
recoveri
thu
leav
author
question
whether
combin
lpvr
nucleosid
analogu
ribavirin
would
result
improv
outcom
trial
explor
therapeut
potenti
lpvr
currentlyongo
http
wwwremapcaporg
coronaviru
http
identifi
key
molecul
cell
invas
see
therapeut
blockad
control
diseas
aid
viral
clearanc
suggest
howev
unselect
ace
blockad
current
avail
agent
may
problemat
could
alter
antiinflammatori
antifibrot
properti
inde
deplet
may
potenti
contribut
increas
diseas
activ
critic
ill
patient
anim
studi
protect
ard
angiotensin
ii
contribut
pulmonari
patholog
includ
edema
fibrosi
thu
accumul
angiotensin
ii
absenc
may
aggrav
diseas
organ
damag
consequ
induct
recent
suggest
treatment
howev
effect
may
vari
tissu
environ
intestin
epithelia
produc
much
higher
level
bronchial
epithelia
notabl
patient
develop
gastrointestin
symptom
symptom
tend
mild
patient
remain
posit
stool
sampl
long
respiratori
specimen
becam
neg
base
observ
one
could
suggest
highlevel
express
seen
intestin
contrast
respiratori
tract
children
young
peopl
compar
individu
risk
elderli
especi
obes
chronic
ill
may
protect
inflamm
tissu
damag
howev
addit
factor
immunolog
microenviron
region
variabl
microbiom
may
significantli
affect
viru
uptak
replic
andor
clearanc
thu
exact
role
context
remain
unveil
may
complex
administr
recombin
human
neutral
virion
prior
attach
host
cell
also
explor
therapeut
option
futur
attempt
exploit
antiinflammatori
effect
ang
ma
axi
relat
ard
first
pilot
trial
human
publish
whilst
data
support
efficaci
ard
treatment
option
remain
outstand
treatment
appear
safe
well
toler
mention
effect
inhibit
express
type
interferon
result
tissu
damag
express
proinflammatori
cytokin
chemokin
infect
monocyt
macrophag
promot
excess
immun
cell
infiltr
cytokin
respons
recent
also
abort
infect
lymphocyt
suggest
detail
character
remain
outstand
altogeth
unalt
viru
replic
presenc
tissu
damag
inflammatori
cytokin
express
explain
ard
cytokin
storm
overcom
immun
evas
enhanc
antivir
activ
may
logic
treatment
strategi
sar
mer
patient
recombin
interferon
use
vari
success
antivir
activ
recombin
shown
vitro
mer
sar
sar
neither
mortal
viral
clearanc
affect
recombin
interferon
mer
howev
time
administr
may
critic
suggest
mous
model
ifn
treatment
mer
therefor
human
patient
may
receiv
treatment
late
fulli
effect
convalesc
plasma
ie
plasma
individu
follow
resolut
rich
immunoglobulin
direct
entertain
possibl
treatment
option
anecdot
use
sar
mer
ebola
influenza
patient
support
use
neutral
andor
immunomodulatori
agent
howev
larger
random
control
assess
hyperimmun
intraven
immunoglobulin
use
sever
influenza
ebola
show
intervent
superior
placebo
similarli
rigor
evalu
data
use
coronavir
infect
lack
use
feasibl
studi
explor
use
mer
found
mani
survivor
antibodi
titr
high
enough
thu
limit
donor
pool
variabl
dose
issu
surround
donor
recruit
time
rapidli
increas
patient
number
drawback
regard
safeti
widespread
use
human
blood
product
limit
avail
util
wide
avail
treatment
option
final
virus
subject
ade
see
nonneutr
antibodi
option
plasma
therapi
also
hold
signific
risk
complic
recent
exemplifi
antizika
viru
antibodi
enhanc
dengu
viru
infect
thu
administr
hyperimmuneconvalesc
plasma
may
carri
risk
signific
ill
upon
futur
exposur
relat
yettoemerg
coronavirus
mention
current
manag
mainli
support
approv
treatment
base
scientif
evid
avail
main
caus
death
includ
ard
cytokin
storm
syndrom
also
refer
macrophag
activ
syndrom
ma
secondari
hemophagocyt
histiocytosi
hlh
inde
ard
occur
patient
cytokin
storm
syndrom
consid
impress
rapid
develop
system
pulmonari
inflamm
subset
patient
earli
identif
control
derail
immun
respons
utmost
import
base
data
chines
cohort
marker
associ
cytokin
storm
condit
may
predict
poor
outcom
includ
leukopenia
lymphopenia
thrombopenia
hypoalbuminemia
significantli
elev
crp
hyperfibringenemia
prolongedthrombin
time
howev
need
test
prospect
sensit
specif
biomark
may
identifi
first
data
cytokin
storm
syndrom
catastroph
effect
tissu
organ
gener
patient
famili
hlh
mutat
associ
gene
includ
lyst
xiap
other
result
system
inflamm
control
death
standard
treatment
condit
includ
highdos
corticosteroid
dexamethason
calcineurin
inhibitor
cyclosporin
chemotherapi
etoposid
ultim
stem
cell
transplant
underli
molecular
caus
famili
hlh
differ
associ
cytokin
storm
syndrom
clinic
fever
organomegali
patient
laboratori
featur
cytopenia
massiv
elev
inflammatori
paramet
includ
crp
esr
ferritin
hypalbuminemia
hyperfibrinogenaemia
etc
consequ
tissu
organ
damag
death
overlap
furthermor
base
observ
influenza
pandem
signific
proport
individu
develop
diseaseassoci
secondari
cytokin
storm
syndrom
may
mutat
one
gene
associ
famili
hlh
fatal
associ
mutat
gene
associ
perforin
pathway
thu
clinic
manag
associ
cytokin
storm
syndrom
may
extent
inform
know
famili
hlh
howev
treatment
associ
cytokin
storm
target
includ
cytotox
drug
andor
stem
cell
transplant
secondari
infect
hope
clear
corticosteroid
use
primari
secondari
form
hlh
control
inflamm
ard
first
preliminari
data
sar
suggest
highdos
steroid
benefici
effect
lung
injuri
instead
highdos
corticosteroid
associ
complic
form
ard
includ
avascular
osteonecrosi
short
cours
lowor
mediumdos
corticosteroid
howev
suggest
benefit
chines
cohort
critic
ill
patient
taken
togeth
limit
data
efficaci
safeti
corticosteroid
ard
anecdot
conclus
control
trial
exist
use
associ
wide
variabl
effect
pathogen
clearanc
evid
efficaci
lack
highdos
corticosteroid
gener
recommend
treatment
use
low
dose
regimen
must
trial
formal
control
studi
intraven
immunoglobulin
ivig
use
system
autoimmuneinflammatori
condit
control
system
inflamm
sever
mechan
includ
captur
activ
complement
factor
blockad
receptor
inhibit
b
lymphocyt
differenti
activ
neutralis
cytokin
antibodi
etc
mention
immun
complex
contain
viabl
viru
may
mediat
infect
activ
receptor
deposit
tissu
organ
lastli
result
proinflammatori
respons
note
ard
cytokin
storm
sar
coincid
serum
convers
major
patient
support
argument
furthermor
patient
ultim
die
seroconvert
significantli
earlier
compar
individu
recov
infect
base
observ
ivig
may
benefit
patient
inhibit
receptor
limit
antibodydepend
enhanc
discuss
furthermor
aforement
classic
antiinflammatori
effect
may
limit
system
inflamm
antipathogen
properti
may
support
case
bacteri
superinfect
patient
previous
clear
develop
specif
antibodi
blockad
cytokin
associ
hyperinflamm
target
approach
compar
use
system
corticosteroid
promis
therapeut
avenu
inde
first
anecdot
report
suggest
efficaci
least
patient
receptor
antagonist
tocilizumab
use
success
patient
secondari
cytokin
storm
syndrom
includ
sever
studi
start
launch
investig
efficaci
safeti
tocilizumab
patient
secondari
cytokin
storm
syndrom
includ
china
recombin
receptor
antagonist
anakinra
origin
develop
control
cytokin
storm
associ
tissu
damag
sepsi
patient
subsequ
anakinra
success
use
patient
cytokin
storm
syndrom
secondari
autoimmuneinflammatori
infecti
malign
diseas
anakinra
may
signific
potenti
control
hyperinflamm
sever
diseas
consid
absenc
sever
sideeffect
aforement
sepsi
trial
reduc
frequenc
neutropenia
hepatotox
compar
tocilizumab
current
anakinra
triall
randomis
placebocontrol
studi
children
adult
associ
cytokin
storm
syndrom
china
inhibit
janu
kinas
jak
small
molecul
rel
new
concept
use
system
autoimmuneinflammatori
condit
jak
involv
cytokin
receptor
signal
includ
limit
receptor
well
type
type
ifn
receptor
mediat
phosphoryl
stat
famili
transcript
factor
turn
involv
proinflammatori
cytokin
express
thu
jak
inhibitor
effici
limit
cytokin
express
may
aid
control
cytokin
storm
howev
jak
also
central
involv
control
express
play
key
role
limit
viru
replic
initi
pathogen
clearanc
least
initi
stage
diseas
viru
replic
infect
may
limit
epithelium
like
limit
express
see
therefor
addit
inhibit
jak
small
molecul
may
counterproduct
limit
pathogen
contain
clearanc
may
caus
unforese
complic
thu
jak
inhibit
may
suitabl
targetdirect
treatment
option
associ
cytokin
storm
syndrom
andor
ard
knowledg
least
two
clinic
trial
ongo
test
efficaci
safeti
jak
inhibitor
sever
previous
discuss
mechan
infect
immun
evas
dysregul
innat
adapt
immun
respons
caus
signific
concern
among
patient
system
immun
modul
treatment
includ
patient
malign
system
autoimmuneinflammatori
diseas
base
previou
coronaviru
outbreak
sar
mer
first
small
observ
studi
cohort
risk
factor
poor
outcom
includ
old
age
presenc
comorbid
diabet
metabol
syndrom
etc
obes
male
sex
coronari
heart
diseas
chronic
obstruct
pulmonari
diseas
kidney
diseas
note
immun
modul
suppress
identifi
risk
factor
poor
prognosi
china
itali
could
gener
consid
good
news
immun
suppress
associ
alter
immun
function
may
predispos
patient
infect
potenti
prolong
viru
spread
furthermor
associ
lymphopenia
patient
receiv
immun
modul
treatment
may
prone
secondari
infect
bacteri
pneumonia
discuss
immun
modul
drug
may
protect
viral
infect
antimalari
drug
chloroquin
hydroxychloroquin
may
inhibit
tissu
infect
viral
replic
furthermor
immun
modul
medic
antimalari
drug
classic
well
biolog
dmard
other
may
prevent
control
cytokin
storm
syndrom
uncontrol
discontinu
immun
modul
treatment
may
result
diseas
flare
autoimmuneinflammatori
condit
organ
reject
transplant
patient
reoccurr
malign
top
obviou
effect
may
also
increas
risk
viral
infect
thu
nation
intern
societi
includ
acr
eular
recommend
continu
treatment
absenc
symptom
alter
exist
treatment
regimen
agreement
close
monitor
respons
clinic
servic
intern
collabor
need
way
safe
assess
individu
risk
vulner
patient
group
reliabl
data
avail
close
clinic
monitor
social
distanc
priorit
immun
exist
signific
proport
human
develop
sever
diseas
novel
coronaviru
threat
million
global
capac
escap
innat
immun
respons
allow
pathogen
produc
larg
copi
number
primarili
infect
tissu
usual
airway
epithelia
infect
innat
immun
cell
andor
recruit
uninfect
cell
circul
primari
site
infect
massiv
immun
reaction
induc
hyperinflamm
result
cytokin
storm
lifethreaten
complic
begin
understand
host
factor
differenti
express
cell
surfac
protein
may
determin
infect
risk
diseas
present
outcom
unveil
tissu
stage
specif
factor
contribut
patholog
result
new
effect
diseas
stage
specif
therapeut
approach
control
viru
replic
limit
inflammatori
damag
vaccin
becom
avail
